In the Latest Big Pharma/RNAi Alliance, Alcon Inks Deal with Dharmacon for Eye Diseases | GenomeWeb

As the field of RNAi-based therapeutics evolves, more and more traditional drugmakers have been entering the field, usually through collaborations with established RNAi players. As of this week, ophthalmology drug developer Alcon has joined the ranks through a drug-discovery collaboration with Dharmacon.

For Dharmacon, the alliance represents the first step towards moving beyond its role as simply an RNAi oligo and tool provider in a market that has become increasingly saturated with competition.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.